Published in Br J Haematol on October 01, 2000
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Prognostic importance of survivin in breast cancer. Br J Cancer (2003) 1.56
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood (2012) 1.25
Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol (2004) 1.13
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood (2009) 1.09
Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes. Haematologica (2012) 0.91
Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res (2008) 0.85
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer (2013) 0.85
Bone marrow cell cycle markers in inherited bone marrow failure syndromes. Leuk Res (2008) 0.84
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene (2014) 0.84
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol (2012) 0.82
SMAC is expressed de novo in a subset of cervical cancer tumors. BMC Cancer (2004) 0.81
Primary breast lymphomas. Rare Tumors (2009) 0.81
Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res (2010) 0.81
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol (2015) 0.81
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs (2013) 0.81
Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol (2010) 0.79
Localization and upregulation of survivin in cancer health disparities: a clinical perspective. Biologics (2015) 0.79
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns. Cancer Manag Res (2009) 0.79
Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One (2014) 0.79
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Invest New Drugs (2014) 0.78
Comparative proteomics in acute myeloid leukemia. Contemp Oncol (Pozn) (2012) 0.77
1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int J Oncol (2009) 0.77
Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na⁺/K⁺-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades. Biochem Pharmacol (2013) 0.77
Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1. Leukemia (2014) 0.77
AML sensitivity to YM155 is modulated through AKT and Mcl-1. Cancer Lett (2015) 0.77
Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia. Haematologica (2013) 0.76
Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investig (2017) 0.75
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med (2016) 0.75
Evodiamine inhibits proliferation and induces apoptosis in gastric cancer cells. Oncol Lett (2015) 0.75
Effects of LG268 on Cell Proliferation and Apoptosis of NB4 Cells. Int J Med Sci (2016) 0.75
Expression and clinical significance of antiapoptotic gene (survivin) in NB4 and acute promyelocytic leukemia cells. ScientificWorldJournal (2012) 0.75
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 4.36
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol (1998) 2.74
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol (1998) 2.64
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res (1998) 2.38
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem (1998) 2.27
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) Br J Haematol (1991) 2.23
The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene (1995) 2.23
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res (2011) 2.23
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 2.22
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell (1993) 2.22
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol (1994) 2.20
Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol (1989) 2.13
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
Induction of the PML protein by interferons in normal and APL cells. Leukemia (1995) 2.05
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood (1995) 2.04
Is there a limit to the normality of blood products? Hematol J (2000) 2.00
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91
The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res (1999) 1.89
Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A (2001) 1.89
Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature (1990) 1.87
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood (1998) 1.87
The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A (1989) 1.86
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Therapy-related acute promyelocytic leukemia. J Clin Oncol (2003) 1.82
PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 1.82
Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem (1999) 1.82
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia (2004) 1.81
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia (2006) 1.77
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) 1.77
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia (2006) 1.76
Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell (2000) 1.70
The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol (1981) 1.64
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest (2001) 1.64
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia (2004) 1.63
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 1.63
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest (1997) 1.61
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol (2004) 1.59
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med (1999) 1.58
Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol (1978) 1.58
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A (1994) 1.57
Cytokine-regulated expression of survivin in myeloid leukemia. Blood (2001) 1.56
Neutrophilic dermatoses during granulocytopenia. Arch Dermatol (1995) 1.56
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 1.56
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
The clinicopathological features of extensive small intestinal CD4 T cell infiltration. Gut (1999) 1.54
Acute leukemia with Burkitt's tumor cells: A study of six cases with special reference to lymphocyte surface markers. Blood (1975) 1.52
A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest (1990) 1.51
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Endothelial cell activation by leukocyte microparticles. J Immunol (1998) 1.49
Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood (1978) 1.47
Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med (1990) 1.46
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 1.45
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia (2005) 1.44
A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia (2001) 1.43
A t(8;14)(q24;q11) translocation in a T-cell leukemia (L1-ALL) with c-myc and TcR-alpha chain locus rearrangements. Int J Cancer (1986) 1.43
Charon's size and an upper limit on its atmosphere from a stellar occultation. Nature (2006) 1.43